INTRODUCTION
============

Chronic obstructive pulmonary disease (COPD) and heart failure (HF) are major global health issues characterized by high mortality and morbidity \[[@r1], [@r2]\]. The COPD-heart failure overlap leads to important therapeutic challenges. The cornerstones of COPD therapy are long-acting inhaled bronchodilators (anticholinergics and β2 agonists) with or without inhaled corticosteroids (ICSs) \[[@r1]\]. Improvements in medical treatment have shifted the treatment of HF from the use of positive inotropic agents to efforts to limit and slow its progression \[[@r2]\]. Angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β blockers, and aldosterone antagonists reduce hospitalization and mortality in patients with HF.

Although β blockers are established therapy for HF, this class of drugs is often underused in patients with COPD-HF overlap \[[@r3]\]. Furthermore, patients receiving ARBs were less likely to have cough compared with those receiving ACEIs \[[@r4]\]. ACEI-related cough could lead to bronchial hyperresponsiveness \[[@r5]\]. Moreover, the presence of bronchial hyperresponsiveness in COPD is associated with increased mortality \[[@r6]\]. More evidence of the survival benefit of this therapy is needed. Therefore, the aim of this study was to investigate the survival effects of medications recommended in guidelines for patients with COPD-heart failure overlap using a population-based nationwide dataset.

RESULTS
=======

Clinical characteristics of the study population
------------------------------------------------

After the application of exclusion criteria, the study cohort consisted of 611,618 patients with COPD alone and 275,436 patients with COPD-heart failure overlap ([Figure 1](#f1){ref-type="fig"}). The mean follow-up periods for the COPD-heart failure overlap and COPD alone cohorts were 9.32 and 9.81 years, respectively. [Table 1](#t1){ref-type="table"} shows the baseline characteristics of the cohorts. The percentage of COPD-heart failure overlap patients increased significantly with age at the time of COPD diagnosis; the greatest proportion of these patients was aged ≥80 years (total, 45.90%; male, 40.56%; female, 53.66%; [Figure 2A](#f2){ref-type="fig"}--[2C](#f2){ref-type="fig"}). Compared with the COPD alone cohort, the COPD-heart failure overlap cohort was older (mean age, 64.38 *vs.* 70.63 years; *p* \< 0.0001) and contained fewer men (64.02% *vs.* 59.14%; *p* \< 0.0001). Compared with the COPD alone cohort, the COPD-heart failure overlap cohort had more outpatient visits (mean, 2.44 *vs.* 2.79), hospitalizations for COPD or HF (mean, 0.15 *vs.* 0.46; all *p* \< 0.0001) per year.

![**Flow diagram summarizing the process of enrollment.**](aging-11-102004-g001){#f1}

###### Characteristics of the COPD-heart failure overlap cohort and COPD alone cohort.

  -------------------------------------------------- --------------------------------------- ----------------------- --------------- ------- ---------
  **Characteristics**                                **COPD-heart failure overlap cohort**   **COPD alone cohort**   ***p* value**           
  ***n***                                            **%**                                   ***n***                 **%**                   
  N                                                  275436                                  611618                                          
  Age, years (mean ± SD)                             70.63±9.87                              64.38±11.83             \<.0001                 
  Age                                                                                                                \<.0001                 
   \<65                                              65199                                   23.67                   287901          47.07   
   ≥65                                               210237                                  76.33                   323717          52.93   
  Follow-up, years(mean ± SD)                        9.32±4.26                               9.81±4.26               \<.0001                 
  Sex                                                                                                                \<.0001                 
   Female                                            112546                                  40.86                   220045          35.98   
   Male                                              162890                                  59.14                   391573          64.02   
  Comorbidities                                                                                                                              
   Diabetes mellitus                                 101903                                  37.00                   180785          29.56   \<.0001
   Hypertension                                      224020                                  81.33                   359818          58.83   \<.0001
   Cerebrovascular disease                           76127                                   27.64                   121677          19.89   \<.0001
   Ischemia heart disease                            143048                                  51.94                   189921          31.05   \<.0001
   Malignancy                                        39000                                   14.16                   105500          17.25   \<.0001
   Cirrhosis                                         68138                                   24.74                   171537          28.05   \<.0001
   Chronic kidney disease                            14457                                   5.25                    8962            1.47    \<.0001
  Charlson Comorbidity Index                                                                                                                 
   0--1                                              87422                                   31.74                   294082          48.08   \<.0001
   \>1                                               188014                                  68.26                   317536          51.92   \<.0001
  Urbanization                                                                                                                               
   I                                                 58921                                   21.39                   157047          25.68   \<.0001
   II                                                113363                                  41.16                   267800          43.78   \<.0001
   III                                               64095                                   23.27                   115765          18.93   \<.0001
   IV                                                39057                                   14.18                   71006           11.61   \<.0001
  Income level                                                                                                                               
   0                                                 64631                                   23.47                   111657          18.26   \<.0001
   1--15840                                          61442                                   22.31                   117733          19.25   \<.0001
   15841--25000                                      129684                                  47.08                   286852          46.90   \<.0001
   ≧25000                                            19679                                   7.14                    95376           15.59   \<.0001
  OPD visit/year(first year)                         2.79±4.96                               2.44±4.26               \<.0001                 
  Exacerbation frequency of COPD (AE/year)                                                                                                   
   0 AE/year                                         134269                                  48.75                   449378          73.47   \<.0001
   \>0, \<1 AE/year                                  117834                                  42.78                   138584          22.66   \<.0001
   ≧1, \<2 AE/year                                   15114                                   5.49                    15384           2.52    \<.0001
   ≧2, \<3 AE/year                                   4586                                    1.66                    4582            0.75    \<.0001
   ≧ 3AE/year                                        3633                                    1.32                    3690            0.60    \<.0001
  Exacerbation frequency of HF (AE/year)                                                                                                     
   0 AE/year                                         116224                                  42.20                                           
   \>0, \<1 AE/year                                  143611                                  52.14                                           
   ≧1, \<2 AE/year                                   11197                                   4.07                                            
   ≧2, \<3 AE/year                                   2792                                    1.01                                            
   ≧ 3AE/year                                        1612                                    0.58                                            
  Hospitalization for COPD and HF/year (mean ± SD)   0.46±0.75                               0.15±0.49               \<.0001                 
  COPD Medications                                                                                                                           
   SABDs                                             271527                                  98.58                   592993          96.95   \<.0001
   LABAs alone                                       69496                                   25.23                   201216          32.90   \<.0001
   ICSs alone                                        53268                                   19.34                   112995          18.47   \<.0001
   ICS/LABA combinations                             60670                                   22.03                   137063          22.41   \<.0001
   LAMA                                              23948                                   8.69                    54519           8.91    \<.0001
  HF Medications                                                                                                                             
   ACEIs                                             178634                                  64.85                   251327          41.09   \<.0001
   ARBs                                              166788                                  60.55                   262085          42.85   \<.0001
   Cardioselective β-blockers                        77381                                   28.09                   124213          20.31   \<.0001
   Non-selective β-blockers                          64739                                   23.50                   60261           9.85    \<.0001
   Loop Diuretics                                    190593                                  69.20                   265535          43.42   \<.0001
   Aldosterone antagonists                           81199                                   29.48                   77585           12.69   \<.0001
   Digoxins                                          105209                                  38.20                   61995           10.14   \<.0001
   Statins                                           88952                                   32.29                   186115          30.43   \<.0001
  -------------------------------------------------- --------------------------------------- ----------------------- --------------- ------- ---------

Abbreviations: COPD, chronic obstructive pulmonary disease; HF, heart failure; SD, standard deviation; OPD, outpatient department; AE, acute exacerbation; SABDs, short-acting bronchodilators; LABAs, long-acting beta-agonists; LAMA, long-acting muscarinic antagonist; ICSs, inhaled corticosteroids; ACEIs, angiotensin-converting-enzyme inhibitors; ARBs, angiotensin receptor blockers.

![(**A**) Percentage of patients with COPD-heart failure overlap (COPD+HF) in different age groups. (**B**) Percentage of patients with COPD-heart failure overlap (COPD+HF) in different age groups in male sex. (**C**) Percentage of patients with COPD-heart failure overlap (COPD+HF) in different age groups in female sex.](aging-11-102004-g002){#f2}

Risk factors for mortality in patients with COPD-heart failure overlap
----------------------------------------------------------------------

The cumulative survival hazard was significantly lower in the COPD-heart failure overlap cohort than in the COPD alone cohort in Kaplan--Meier analysis (log-rank test, *p* \< 0.001; [Figure 3A](#f3){ref-type="fig"}). Survival decreased significantly with increasing exacerbation frequency of COPD or HF in Kaplan--Meier analysis ([Figure 3B](#f3){ref-type="fig"} and [3C](#f3){ref-type="fig"}); this result was sustained after adjustment for other factors ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). We identified the following independent risk factors for mortality in the COPD-heart failure overlap cohort: age ≥ 65 years (HR, 1.59; 95% CI, 1.59--1.60), male sex (HR, 1.11; 95% CI, 1.11--1.12), diabetes mellitus (HR, 1.07; 95% CI, 1.07--1.07), hypertension (HR, 1.05; 95% CI, 1.04--1.05), cerebrovascular disease (HR, 1.06; 95% CI, 1.06--1.06), malignancy (HR, 1.24; 95% CI, 1.24--1.24), chronic kidney disease (HR, 1.03; 95% CI, 1.03--1.03), and Charlson Comorbidity Index \> 1 (HR, 1.03; 95% CI, 1.03--1.03; all *p* \< 0.0001; [Supplementary Table 1](#SD1){ref-type="supplementary-material"}).

![(**A**) Survival of patients with COPD alone or COPD-heart failure overlap (COPD + HF). (**B**) Survival of patients with COPD. (**C**) Survival of patients with HF.](aging-11-102004-g003){#f3}

The effect of COPD medication use on mortality
----------------------------------------------

In the time-dependent Cox proportional-hazards model, the use of LAMA, and ICS/LABA combinations was associated with significantly lower mortality risks (model 1: LAMA: HR = 0.76, 95% CI = 0.75--0.77; ICS/LABA combinations: HR = 0.74, 95% CI = 0.74--0.75; model 2: LAMA: HR = 0.80, 95% CI = 0.79--0.81; ICS/LABA combinations: HR = 0.77, 95% CI = 0.77--0.78; all *p \<* 0.0001; [Table 2](#t2){ref-type="table"}). In contrast, use of ICSs alone was associated with significantly higher mortality risks. The results of subgroup analyses are presented in [Figure 4A](#f4a){ref-type="fig"}--[4E](#f4b){ref-type="fig"}.

###### Sensitivity analyses for medication effects on mortality in COPD-heart failure overlap patients.

  ----------------------------------------- -------------------------- ----------------- ------------------- ---------
  **Variables**                             **Time-dependent model**                                         
  **Model 1^\#^**                           **Model 2^\#\#^**                                                
  **HR (95% CI)**                           ***p***                    **HR (95% CI)**   ***p***             
  **COPD Medication**                                                                                        
  Non-users of SABDs                        Reference                                    Reference           
   SABDs                                    1.06 (1.06--1.07)          \<.0001           1.06 (1.06--1.06)   \<.0001
  Non-users of LABAs alone                  Reference                                    Reference           
   LABAs alone                              1.04 (1.03--1.04)          \<.0001           1.05 (1.05--1.06)   \<.0001
  Non-users of ICSs alone                   Reference                                    Reference           
   ICSs alone                               1.08 (1.08--1.09)          \<.0001           1.09 (1.08--1.10)   \<.0001
  Non-users of ICS/LABA combinations        Reference                                    Reference           
   ICS/LABA combinations                    0.74 (0.74--0.75)          \<.0001           0.77 (0.77--0.78)   \<.0001
  Non-users of LAMA                         Reference                                    Reference           
   LAMA                                     0.76 (0.75--0.77)          \<.0001           0.80 (0.79--0.81)   \<.0001
  **HF Medication**                                                                                          
  Non-users of ACEIs                        Reference                                    Reference           
   ACEIs                                    1.08 (1.08--1.08)          \<.0001           1.11 (1.11--1.12)   \<.0001
  Non-users of ARBs                         Reference                                    Reference           
   ARBs                                     0.76 (0.76--0.76)          \<.0001           0.80 (0.79--0.80)   \<.0001
  Non-users of Cardioselective β-blockers   Reference                                    Reference           
   Cardioselective β-blockers               0.72 (0.71--0.72)          \<.0001           0.76 (0.76--0.77)   \<.0001
  Non-users of Non-selective β-blockers     Reference                                    Reference           
   Non-selective β-blockers                 0.92 (0.92--0.93)          \<.0001           0.96 (0.95--0.96)   \<.0001
  Non-users of Loop diuretics               Reference                                    Reference           
   Loop diuretics                           1.07 (1.07--1.07)          \<.0001           1.09 (1.08--1.09)   \<.0001
  Non-users of Aldosterone antagonists      Reference                                    Reference           
   Aldosterone antagonists                  0.96 (0.96--0.96)          \<.0001           0.99 (0.98--0.99)   0.0002
  Non-users of Digoxins                     Reference                                    Reference           
   Digoxins                                 1.13 (1.12--1.13)          \<.0001           1.12 (1.12--1.13)   \<.0001
  Non-users of Statins                      Reference                                    Reference           
   Statins                                  0.75 (0.74--0.75)          \<.0001           0.76 (0.76--0.77)   \<.0001
  ----------------------------------------- -------------------------- ----------------- ------------------- ---------

Abbreviations: COPD, chronic obstructive pulmonary disease; HF, heart failure; HR, hazard ratio; CI, confidence interval; AE, acute exacerbation; SABDs, short-acting bronchodilators; LABAs, long-acting beta-agonists; LAMA, long-acting muscarinic antagonist; ICSs, inhaled corticosteroids; ACEIs, angiotensin-converting-enzyme inhibitors; ARBs, angiotensin receptor blockers.

HRs were adjusted for age, sex, income level, comorbidities, exacerbation frequency of COPD, exacerbation frequency of HF, Charlson Comorbidity Index, urbanization level and medications. All factors with *p* \< 0.1 in univariate analyses were included in the Cox multivariate analysis.

^\#^Medications were analyzed as time-dependent covariates (time period: 3 months).

^\#\#^Medications were analyzed as time-dependent covariates (time period: 1 year)

![(**A**) Subgroup analysis of SABDs. (HRs were adjusted for age, sex, income level, comorbidities, exacerbation frequency of COPD, exacerbation frequency of HF, Charlson Comorbidity Index, urbanization level and medications; medications were analyzed as time-dependent covariates, time period: 3 months). (**B**) Subgroup analysis of LABAs alone. (**C**) Subgroup analysis of ICSs alone.](aging-11-102004-g004){#f4a}

![(**D**) Subgroup analysis of ICS/LABA combinations. (**E**) Subgroup analysis of LAMA. (**F**) Subgroup analysis of ACEIs.](aging-11-102004-g005){#f4b}

![(**G**) Subgroup analysis of ARBs. (**H**) Subgroup analysis of cardioselective β blockers. (**I**) Subgroup analysis of non-selective β blockers.](aging-11-102004-g006){#f4c}

![(**J**) Subgroup analysis of loop diuretics. (**K**) Subgroup analysis of aldosterone antagonists. (**L**) Subgroup analysis of digoxins.](aging-11-102004-g007){#f4d}

![(**M**) Subgroup analysis of statin.](aging-11-102004-g008){#f4e}

The effect of HF medication use on mortality
--------------------------------------------

Among HF medication, the use of ARBs, cardioselective β blockers, non-selective β blockers, aldosterone antagonists, and statins was associated with significantly lower mortality risks (model 1: ARBs: HR = 0.76, 95% CI = 0.76--0.76; cardioselective β blockers: HR = 0.72, 95% CI = 0.71--0.72; non-selective β blockers: HR = 0.92, 95% CI = 0.92--0.93; aldosterone antagonists: HR = 0.96, 95% CI = 0.96--0.96; statins: HR = 0.75, 95% CI = 0.74--0.75; model 2: ARBs: HR = 0.80, 95% CI = 0.79--0.80; cardioselective β blockers: HR = 0.76, 95% CI = 0.76--0.77; non-selective β blockers: HR = 0.96, 95% CI = 0.95--0.96; aldosterone antagonists: HR = 0.99, 95% CI = 0.98--0.99; statins: HR = 0.76, 95% CI = 0.76--0.77; all *p \<* 0.001; [Table 2](#t2){ref-type="table"}). However, digoxins use was associated with the highest mortality risk. The results of subgroup analyses are presented in [Figure 4F](#f4b){ref-type="fig"}--[4M](#f4e){ref-type="fig"}.

Validation of COPD and HF definitions
-------------------------------------

2,325 patients with COPD and 3,402 patients with HF were identified from the claims database of Taipei Veterans General Hospital. Then, 300 patients from each group were randomly selected for validation of diagnoses. Of them, 276 patients with COPD underwent pulmonary function test and 288 patients with HF underwent echocardiogram. Diagnoses of COPD were confirmed by pulmonologists in 282/300 subjects (94.0% sensitivity) and by pulmonary function test in 238/276 subjects (86.2% sensitivity). Diagnoses of HF were confirmed by cardiologists in 289/300 subjects (96.3% sensitivity) and by echocardiography in 263/288 subjects (91.3% sensitivity).

DISCUSSION
==========

This study revealed a greater medical burden in patients with COPD-heart failure overlap than in those with COPD alone. Our study demonstrated significant reductions in mortality associated with the use of LAMA, ICS/LABA combinations, ARBs, β blockers, aldosterone antagonists, and statins in patients with COPD-heart failure overlap. Results of this study, which involved large COPD-heart failure overlap and COPD cohorts -- to our knowledge, the largest COPD-heart failure overlap cohort examined to date -- are more valuable than those of clinical trials because they more closely reflect real-world practice. Furthermore, the definitions of COPD and HF were validated in this study, which indicated that the accuracy was excellent.

Despite the Heart Failure Society of America's recommendation of β blocker use for HF \[[@r2]\], we previously documented the suboptimal use of β blockers in patients with COPD-heart failure overlap due to concern about their detrimental effects on COPD \[[@r7]\]. A population-based survey conducted by Lipworth *et al*. in UK enrolled 24,237 patients with HF alone and 10,853 patients with COPD-heart failure overlap, and showed that the use of β blockers in combination with ACEI/ARB was much lower in patients with COPD-heart failure overlap than in patients with HF alone (22.3% *vs.* 41.3%, *p* \< 0.001) \[[@r3]\]. In turn, despite the Global Initiative for Chronic Obstructive Lung Disease's recommendation of bronchodilator use in patients with COPD and COPD-heart failure overlap \[[@r1]\], concern about detrimental effects on HF has led to suboptimal use of these drugs \[[@r8]\].

This study demonstrated that LAMA, ICS/LABA combinations, ARBs, β blockers, aldosterone antagonists, and statins reduced mortality in patients with COPD-heart failure overlap. We also showed that cardioselective β blockers (bisoprolol and metoprolol) yield better survival outcomes than do non-selective β blockers in patients with COPD-heart failure overlap. Pulmonary effects appear to differ among β blockers; non-selective, but not cardioselective, β blockers have been found to reduce forced expiratory volume in 1 second (FEV~1~) and to increase airway hypersensitiveness in patients with COPD \[[@r9]\]. In a randomized cross-over study \[[@r10]\], bisoprolol is better tolerated than carvedilol on lung function in patients with moderate to severe COPD.

Paradoxically, as evidence for the efficacy of β blockers in COPD accumulates, studies have shown adverse cardiovascular effects of β agonists. The cardiac safety of LABA treatment, reported in clinical trials, is a result of administration by inhalation, which limits the transition of active drugs into the systemic circulation. However, inhaled β agonists still reach the systemic circulation through pulmonary circulation or absorption *via* the gastrointestinal tract after the swallowing of residual particles \[[@r11]\]. β agonists are associated with increased mortality and HF-related hospitalization in patients with existing HF \[[@r12]\]. A meta-analysis of randomized placebo-controlled trials showed that β-agonist treatment significantly increased the risk of a cardiovascular event in patients with obstructive airway disease compared with placebo (relative risk \[RR\] = 2.54; 95% CI, 1.59--4.05) \[[@r13]\]. Not surprisingly, SABDs and LABAs alone use was associated with increased risk of mortality in this study. Tiotropium, an inhaled LAMA approved for COPD maintenance treatment that was examined in this study, was associated with lower mortality than placebo in clinical trial \[[@r14]\]. In clinical trial \[[@r15]\], use of ICS/LABA combination over three years showed a decrease in mortality that almost reached statistical significance (HR=0.825, *p* = 0.052). A meta-analysis of randomized controlled trials showed that ICS/LABA combinations use was associated with a lower risk of death compared with use of ICSs alone \[[@r16]\]. According to international guideline for COPD \[[@r1]\], ICS monotherapy is not recommended for the management of COPD. Among older patients with COPD, ICS/LABA combinations use was associated with a lower risk of death compared with use of LABAs alone \[[@r17]\]. Sensitivity and subgroup analyses demonstrated that the benefits of LAMA and ICS/LABA combinations in patients with COPD and HF were consistent.

The most common side effect of ACEI therapy is cough, the prevalence of which approaches 50% in Chinese populations \[[@r18]\]. The incidence of ACEI-related cough has been reported to be 2.7 folds higher in Chinese subjects compared with Caucasians \[[@r19]\]. ACEI-induced cough may represent bronchial hyperresponsiveness in some patients \[[@r5]\]. ARBs do not appear to induce cough or bronchial hyperreactivity in patients with symptomatic asthma \[[@r20]\]. Indeed, bronchial hyperresponsiveness is an independent predictor of mortality in COPD patients \[[@r6]\]. In this study, almost all enrollees were Taiwanese. Our study showed that ARBs use is associated with better survival outcomes than ACEIs use. Similarly, use of statins (RR = 0.53; 95% CI, 0.43--0.65) and ARBs (RR = 0.62; 95% CI, 0.44--0.87), but not ACEIs (RR = 1.04; 95% CI, 0.86--1.25), was associated with survival benefit in 22,784 patients with COPD and high cardiovascular risk in a time-matched nested case-control study \[[@r21]\]. In a double-blind, placebo-controlled, randomized controlled trial \[[@r22]\], 80 patients with at least moderate COPD were randomized to either 10 weeks of therapy with an ACEI (10 mg enalapril) or placebo. Use of the ACEI significantly reduced the peak power response to exercise training in COPD patients. Recently, a population-based cohort study \[[@r23]\] also showed that statins use was associated with a lower mortality risk in patients with COPD.

In this study, use of SABDs, loop diuretics, and digoxins increased mortality risk in patients with COPD-heart failure overlap. Possible explanations for the higher mortality risk associated with SABD use are related to various cardiac side effects. In addition, excess SABD, loop diuretic, and digoxin use has been associated with poor control of COPD and HF, which may itself be the cause of this increased risk. Regardless of whether the association demonstrated is causal, however, chronic use of these drugs is a very powerful marker of high mortality risk in patients with COPD-heart failure overlap. Such patients warrant special attention.

This study was strengthened by using a nationwide population-based data to conduct a real-world study, which enrolled nearly all cases of COPD and HF in Taiwan with minimal selection and referral biases, as the NHI coverage rate is \>99% and all cardiopulmonary-related healthcare is covered. To minimize immortal time bias, medication use was analyzed using time-dependent covariates in the Cox proportional-hazards model. Nevertheless, this study has some limitations. First, the claim-based dataset omitted some personal information, such as data on smoking and obesity. Although these factors appear to have no influence on medication selection and we made every effort to correct for confounding factors. Second, we could not assess drug adherence directly. However, this bias is toward the null hypothesis and would lead to underestimation of the actual effects of medications. Finally, the external validity of the results of this study should be of concern because all enrollees were Taiwanese. The generalizability of our findings to non-Asian populations must be further verified.

METHODS
=======

Data Source
-----------

This cohort study used the Taiwan National Health Insurance Research Database (NHIRD), which is derived from the claims data of the Taiwan's National Health Insurance (NHI) program, initiated in 1995, from more than 99% of Taiwan's 23 million residents \[[@r24]\]. The NHIRD, provided for research purposes by Taiwan's National Health Research Institute, contains healthcare data from NHI participants, including information on demographic characteristics; medical diagnoses, procedure, expenditure, and all detailed prescriptions. The accuracy of diagnoses recorded in the NHIRD, such as sleep apnea \[[@r24]\], pneumonia \[[@r24]\], asthma \[[@r25]\], COPD \[[@r25]\], tuberculosis contact \[[@r26]\], and tuberculosis \[[@r27]\] has been validated in our previous work. The study was exempted from full review by the Institutional Review Board of Taipei City Hospital because the datasets consisted of de-identified secondary data.

Study design and population
---------------------------

In this nationwide cohort study, we retrospectively analyzed medication effects on mortality in patients with COPD-heart failure overlap. All patients with COPD diagnoses recorded in the NHIRD between 1 January 1997 and 31 December 2012 were divided into the COPD alone and COPD-heart failure overlap cohorts. COPD and HF were identified using diagnostic codes from the International Classification of Diseases, 9^th^ Revision, Clinical Modification (HF: 425.4, 425.9, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, and 428.xx; COPD: 491.xx, 492.xx, and 496.xx). Patients with at least six recorded outpatient visits or one hospitalization for either disease were enrolled and followed until the date of death, withdrawal from insurance, or 31 December 2013. Information on the use of medications recommended in guidelines for patients with COPD or HF were extracted \[[@r1], [@r28]\]. Patients with follow-up periods \< 1 year, those aged \< 40 years, and those who were not prescribed medications for COPD or HF were excluded.

Potential confounders and severity classification
-------------------------------------------------

In the investigation of the effects of medications on mortality, age, sex, urbanization level, income level, Charlson Comorbidity Index, exacerbation frequency of COPD, exacerbation frequency of HF, and comorbidities were considered to be potential confounders. Because the most important factor in classifying COPD severity appears to be a previous history of exacerbations \[[@r29]\], exacerbation frequency of COPD was determined using the annual frequency of hospitalizations and emergency department visits for acute exacerbation during the follow-up period. Exacerbation frequency of HF was classified in the same way and the negative correlation between COPD/HF severity and cumulative survival has been validated in our previous study \[[@r7]\]. Based on the number of acute exacerbations (AE) per year, patients were assigned to the 0 AE/year, \>0 and \<1 AE/year, ≥1 and \<2 AE/year, ≥2 and \<3 AE/year, and ≥3 AE/year groups.

Exposure to COPD and HF medications
-----------------------------------

Patients who took ≥28 days of each medication recommended in guidelines for patients with COPD or HF during the follow-up period, were assigned to respective medication groups. Prescriptions of medications for COPD or HF were assessed during each time period (3 months or 1 year) for each individual patient \[[@r30]\]. A 3-month period was chosen, because medications are usually prescribed for 3 months at a time. A 1-year period was used to recheck the robustness of the results of 3-month period. COPD medication groups were: short-acting bronchodilators (SABDs), including short-acting β2 agonists (albuterol, fenoterol, terbutaline, procaterol) and short-acting muscarinic antagonists (ipratropium); long-acting β2 agonists (LABAs; salmeterol, formoterol, bambuterol, indacaterol); long-acting muscarinic antagonist (LAMA; tiotropium); ICSs (budesonide, fluticasone, beclomethasone) and ICS/LABA combinations (fluticasone/salmeterol, budesonide/formoterol, beclomethasone/formoterol). HF medication groups were: ACEIs (benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, perindopril, quinapril, ramipril), ARBs (losartan, candesartan, valsartan, irbesartan, telmisartan, eprosartan, olmesartan, azilsartan), cardioselective β blockers (bisoprolol, metoprolol), non-selective β blockers (carvedilol), loop diuretics (furosemide, bumetanide), aldosterone antagonists (spironolactone, eplerenone); digoxins (digoxin, digitoxin), and statins (atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin).

Validation
----------

The claims database of Taipei Veterans General Hospital (a 3,035-bed tertiary referral hospital in Taiwan) was used to validate the accuracy of the diagnoses of COPD and HF in this study. The contents of this database are used for reimbursement and are similar to those of the NHIRD \[[@r24]--[@r27]\]. The diagnoses of COPD and HF were validated by analysis of selected samples from this database using the same criteria. COPD was defined as COPD diagnosed by a pulmonologist, or fixed airflow limitation determined by pulmonary function test \[[@r1]\]. HF was defined as HF diagnosed by a cardiologist, or inadequate cardiac output determined by echocardiography \[[@r2]\]. Random sampling of claims data for validation was performed using SPSS version 20.

Statistical analyses
--------------------

Data entry and analysis were performed using SAS statistical software (version 9.4; SAS Institute, Cary, NC, USA). Descriptive analysis was used to compare the COPD alone group and COPD-heart failure overlap group in terms of demographic data and the prescription medications during the study period. All the data were presented as mean ± standard deviation (SD) or percentage (%). Comparison between two groups was made by independent Student's t-test for continuous variables or Pearson's chi-square test for categorical variables as appropriate. Kaplan-Meier survival analysis and the log-rank test were used to examine the difference between the cohorts. We used the Cox proportional-hazards regression models to determine the survival effect of medication use during the follow-up period. Medication prescriptions in each 3-month and 1-year period served as time-dependent covariates. Patients who were prescribed ≥28 days of each medication within each interval were assigned to the respective medication groups and all others were defined as non-users \[[@r25]\]. Other baseline variables were analyzed as non--time-dependent covariates. All factors with *p* values \< 0.1 in univariate analyses were included in the Cox multivariate analysis. The hazard ratio (HR) and 95% confidence intervals (CIs) were calculated after adjustment for possible confounding factors. Two-tailed *p* values \< 0.05 were considered statistically significant. Subgroup analyses were performed according to age, sex, exacerbation frequency of COPD and HF.

CONCLUSIONS
===========

This study demonstrated that patients with COPD-heart failure overlap have more outpatient visits per year, more hospitalization, and a shorter time to mortality than do patients with COPD alone. LAMA, ICS/LABA combination, ARB, β blocker, aldosterone antagonist, and statin use decreased the mortality risk.
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